Gonorrhoea, a common sexually transmitted infection (STI) that often doesn't come with symptoms, has become harder to treat as bacteria develop resistance to existing antibiotics. If left untreated, it can cause serious problems such as pelvic inflammatory disease or infertility.
Zoliflodacin, the first new antibiotic developed exclusively for the treatment of this infection in decades, aims to fight drug-resistant superbugs and it is expected to receive marketing approval in the United States.
